Novo Nordisk signs $2.6bn GLP-1 and GIP dual receptor deal
Novo Nordisk has has secured an exclusive global licensing agreement with Hengrui Pharma for HRS-1596. Announced on September 29, the deal provides Novo with the rights to develop, manufacture, and commercialise this once weekly oral GLP-1 and GIP dual receptor agonist in all territories except mainland China, Hong Kong, Macao, and Taiwan. For investors and operators, the transaction structure signals…